Relapsed or Refractory Acute Myeloid Leukemia (AML) Market Outlook

Thelansis’s “Relapsed or Refractory Acute Myeloid Leukemia (AML) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Acute Myeloid Leukemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Relapsed or Refractory Acute Myeloid Leukemia (AML) Overview

Relapsed or refractory acute myeloid leukemia (r/r AML) is a clinically aggressive haematological malignancy defined by disease recurrence following remission or failure to achieve remission after induction chemotherapy, carrying substantially poor prognosis with conventional salvage approaches. Resistance mechanisms encompass clonal evolution, acquisition of additional somatic mutations, leukaemic stem cell persistence, and bone marrow microenvironment-mediated chemotherapy evasion. Restaging bone marrow biopsy with comprehensive cytogenetic and molecular mutation profiling is essential, as mutational landscape evolution frequently occurs at relapse and directly informs therapeutic selection. Targeted agents have transformed the r/r AML landscape; gilteritinib is the definitive approved monotherapy standard for FLT3-mutant relapsed disease, while IDH1 inhibitors ivosidenib and olutasidenib, and IDH2 inhibitor enasidenib, address their respective molecularly defined subgroups with meaningful response rates. Menin inhibitors, including revumenib and ziftomenib, represent the most significant recent therapeutic advance, inducing deep molecular remissions in highly refractory KMT2A-rearranged and NPM1-mutated AML where chemotherapy fails. Venetoclax-based combinations retain broad relevance across molecular subgroups. Gemtuzumab ozogamicin addresses CD33-positive relapsed disease. Intensive salvage chemotherapy bridges eligible patients to allogeneic stem cell transplantation, the only potentially curative option. Prognosis remains poor; clinical trial enrolment, goals-of-care discussions, and early palliative integration are indispensable to compassionate patient-centred management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)